-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $188

Benzinga·12/11/2025 13:29:20
Listen to the news
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $183 to $188.